R. Balabanska

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial

Man‐Fung Yuen, R. Balabanska, Emmanuelle Cottreel et al. · The Lancet Infectious Diseases · 2022 · 42 citations

Medicine, Pharmacology, Clinical Pharmacology +4

The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase 2b trial

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · 2020 · 22 citations

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

Jinlin Hou, Edward Gane, R. Balabanska et al. · Clinical and Molecular Hepatology · 2024 · 10 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17